Growth of bipolar disorder market will be curbed by generic erosion
The bipolar disorder market is expected to grow from $4.1 billion in 2020 to $4.9 billion by 2030 across the eight major markets (8MM: the USA, France, Germany, Italy, Spain, UK, Japan and Canada) at a compound annual growth rate (CAGR) of 1.7%.
According to analytics firm GlobalData, main driver of growth will be the launch of seven new pipeline products throughout the 8MM. However, despite these new product launches, only modest growth is expected in the bipolar disorder market due to generic erosion.
GlobalData’s neurology analyst Philippa Salter comments: “The bipolar disorder market is crowded and competitive, with a large number of products available for the treatment of patients, the majority of which are available as inexpensive generics. However, the new pipeline products will have significantly higher costs when compared with these generic products, which will drive market growth.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze